Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An amyloidosis that is characterized by both Ig heavy chains and LC contribute to the amyloid fibrils.
Biomarker and diagnostic research for immunoglobulin heavy-and-light chain has been reported in the published literature.
No clinical trials have been registered for immunoglobulin heavy-and-light chain.
5 publications have been identified in PubMed for immunoglobulin heavy-and-light chain. Research spans Diagnostic / Biomarker (40%), Basic Science / Preclinical (40%), and Other (20%).
Capel HL (2026). [PMID: 41723256](https://pubmed.ncbi.nlm.nih.gov/41723256/). *Commun Biol*. [Basic Science / Preclinical]
Guo D (2026). [PMID: 41254366](https://pubmed.ncbi.nlm.nih.gov/41254366/). *Nat Methods*. [Basic Science / Preclinical]
Wang J (2025). [PMID: 40063611](https://pubmed.ncbi.nlm.nih.gov/40063611/). *Oncologist*. [Diagnostic / Biomarker]
Wang Y (2025). [PMID: 40202538](https://pubmed.ncbi.nlm.nih.gov/40202538/). *Ann Hematol*. [Diagnostic / Biomarker]
Yu T (2024). [PMID: 39544294](https://pubmed.ncbi.nlm.nih.gov/39544294/). *Front Oncol*. [Other]
Data assembled from 2 of 12 sources · Last updated Sep 18, 2026, 8:05 PM UTC